Drugs.com - Clinical Trials

New Study Demonstrates Actemra (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients

Fri, 09 May 2008 13:50:18 GMT

- Fifth International Phase III Study Shows Positive Results with X-ray Data - NUTLEY, N.J., May 09, 2008 /PRNewswire/ -- Roche today announced one-year results from a new two-year Phase III study showing that ACTEMRA(TM) (tocilizumab) can...

Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

Thu, 08 May 2008 20:50:01 GMT

TAMPA, Fla., May 08, 2008 /PRNewswire-FirstCall/ -- Alpharma Inc. , a global specialty pharmaceutical company, today announced results from clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered...

BioDelivery Sciences Presents Phase III BEMA Fentanyl Data

Thu, 08 May 2008 20:10:53 GMT

BEMA(tm) Fentanyl Phase III Data Demonstrating Efficacy and Tolerability to be Presented at American Pain Society Annual Meeting RALEIGH, N.C., May 8, 2008 - BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and commercial partner Meda...

Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting

Thu, 08 May 2008 17:05:11 GMT

Efficacy and safety data support potential of asenapine in the treatment of schizophrenia and bipolar I disorder WASHINGTON, May 08, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that an overview of asenapine clinical...

Collegium Pharmaceutical Inc. Presents Clinical Data for DETERx Abuse-Deterrent Sustained Release Technology at American Pain Society Meeting

Thu, 08 May 2008 17:05:06 GMT

CUMBERLAND, R.I.--(BUSINESS WIRE)--May 8, 2008 - Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced the presentation of a scientific poster summarizing the results of a pharmacokinetic study for its...

Results of the Phase III Pivotal Study of Vyvanse (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists

Thu, 08 May 2008 17:00:15 GMT

VYVANSE demonstrated significant improvement in ADHD symptoms in adults WASHINGTON, May 08, 2008 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which...

Next Pharmaceuticals Announces a New Clinical Study Demonstrating Relora Significantly Relieves Short-Term Anxiety in Healthy Women

Thu, 08 May 2008 16:50:12 GMT

SALINAS, Calif.--(BUSINESS WIRE)--May 8, 2008 - Next Pharmaceuticals announced today the results of a six-week, double-blind, placebo-controlled clinical study on Relora conducted on healthy women between the ages of 20 and 50. Relora significantly...

Data Show FLECTOR Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions

Thu, 08 May 2008 15:50:57 GMT

Patch Formulation May Provide New Option for Clinicians Concerned About Systemic Exposure When Using an Oral NSAID TAMPA, Fla., May 08, 2008 /PRNewswire-FirstCall/ -- Alpharma Inc. , a leading global specialty pharmaceutical company, announced today...

Aethlon Medical Releases Smallpox Related Research Data

Thu, 08 May 2008 15:11:01 GMT

SAN DIEGO--(BUSINESS WIRE)--May 8, 2008 - Aethlon Medical, Inc. (OTCBB:AEMD) today disclosed that researchers have completed in vitro studies that verify the ability of the Aethlon Hemopurifier(R) to effectively capture monkeypox virus (MPV)....

GATTEX Abstracts Accepted for Presentation at DDW Conference; Phase 3 Short Bowel Syndrome Results Scheduled for Oral Plenary Session

Thu, 08 May 2008 14:15:39 GMT

BEDMINSTER, N.J.--(BUSINESS WIRE)--May 8, 2008 - NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced that three abstracts related to the company's development program for GATTEX(TM) (teduglutide) for intestinal failure associated with short...

BEMA(TM) Fentanyl Phase III Data Demonstrating Efficacy and Tolerability to be Presented at American Pain Society Annual Meeting

Thu, 08 May 2008 13:35:34 GMT

RALEIGH, N.C.--(BUSINESS WIRE)--May 8, 2008 - BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and commercial partner Meda Pharmaceuticals will present today and tomorrow, data from Phase III clinical pivotal trials for BEMA Fentanyl, a...

Discovery Labs KL-4 Surfactant Technology Displays Antimicrobial Properties and Does Not Induce Immune Response in Preclinical Models

Thu, 08 May 2008 13:30:37 GMT

Data Presented At Pediatric Academic Societies Annual Meeting WARRINGTON, Pa., May 7, 2008 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announced that new data supporting potential unique properties of its novel KL-4...

New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain

Thu, 08 May 2008 13:30:20 GMT

Results presented at the 27th Annual Meeting of the American Pain Society (APS) SMYRNA, Ga., May 08, 2008 /PRNewswire/ -- Patients treated with lacosamide demonstrated sustained pain relief from diabetic neuropathic pain (DNP), compared to...

New Abbott Study of Investigational Vicodin CR Meets Primary Efficacy Endpoints in Phase III Trial

Thu, 08 May 2008 13:25:42 GMT

Vicodin CR (hydrocodone bitartrate and acetaminophen) Extended Release Tablets Twice-daily Regimen Significantly Lowered Chronic Low Back Pain Intensity with 12-hour Dosing Compared to Placebo TAMPA, May 08, 2008 /PRNewswire-FirstCall/ -- New Phase...

Array BioPharma Presents Additional Positive Phase 2 Results in Inflammatory Pain Clinical Trial at the American Pain Society's Annual Scientific Meeting

Thu, 08 May 2008 13:20:54 GMT

BOULDER, Colo.--(BUSINESS WIRE)--May 7, 2008 - Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Medical Officer, John Yates, M.D., presented additional positive results from a Phase 2 clinical trial evaluating the efficacy of...

Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory Candidates, AN2728 and AN2898, at the International Investigative Dermatology 2008 Conference

Thu, 08 May 2008 13:20:50 GMT

PALO ALTO, Calif., May 08, 2008 /PRNewswire/ -- Anacor Pharmaceuticals announced today that it will present six posters on topical anti-inflammatory candidates, AN2728 and AN2898, at the upcoming International Investigative Dermatology 2008...

KeyNeurotek Pharmaceuticals Reports Positive Phase I Data of Its Cannabinoid Receptor-Agonist

Thu, 08 May 2008 13:15:38 GMT

MAGDEBURG, Germany, May 08, 2008 - KeyNeurotek Pharmaceuticals AG, a biotechnology company focused on the development and marketing of drugs against autoimmune diseases and degenerative disorders of the central nervous system (CNS),...

Discovery Labs Presents Surfaxin Data At Pediatric Academic Societies Annual Meeting

Thu, 08 May 2008 13:15:06 GMT

Discovery Labs Presents SURFAXIN Data At Pediatric Academic Societies Annual Meeting WARRINGTON, Pa., May 7, 2008 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announced that Surfaxin pre-clinical and clinical data were presented...

Savient Reports Favorable Interim Data from Puricase (pegloticase) Open Label Extension Study

Wed, 07 May 2008 22:30:14 GMT

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--May 7, 2008 - Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), today announced positive interim data from the ongoing pegloticase open label extension (OLE) to the Phase 3 pivotal trials in patients...

Clinical Data on Somaxon Pharmaceuticals' Product Candidate for the Treatment of Insomnia Presented at American Psychiatric Association Annual Meeting

Wed, 07 May 2008 22:15:30 GMT

SAN DIEGO--(BUSINESS WIRE)--May 7, 2008 - Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in...

iGuard.org Presents New Data on Statins at FDA Workshop Demonstrating How Patient-Reported Information Can Enhance Drug Safety Knowledge

Wed, 07 May 2008 20:30:18 GMT

WASHINGTON, May 07, 2008 /PRNewswire/ -- Dr. Hugo Stephenson, founder and CEO of iGuard.org, and specialist in epidemiology and drug safety, today presented new insight about the cholesterol lowering drugs, referred to as "statins" to the U.S. Food...

Study Demonstrates Lexapro Significantly Improves Depression Symptoms in Adolescents

Wed, 07 May 2008 20:00:18 GMT

Phase III Data Presented at American Psychiatric Association Annual Meeting WASHINGTON, May 07, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. announced today that study results show Lexapro (escitalopram oxalate) significantly improved...

Shire's Investigational Nonstimulant ADHD Treatment Intuniv (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose

Wed, 07 May 2008 19:30:08 GMT

WASHINGTON, May 07, 2008 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist....

New Analysis in Boys and Girls Shows the ADHD Patch, Daytrana (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months

Wed, 07 May 2008 19:25:23 GMT

WASHINGTON, May 07, 2008 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA(TM)...

Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease

Wed, 07 May 2008 19:25:16 GMT

CAMBRIDGE, Mass., May 07, 2008 /PRNewswire-FirstCall/ -- Genzyme Corp. reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compound...

Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder

Wed, 07 May 2008 19:10:52 GMT

Phase II Data Demonstrate Abbott's Most Advanced NNR Candidate ABT-089 Shows Strong Safety, Tolerability And Efficacy in Adults With ADHD ABBOTT PARK, Ill., May 07, 2008 /PRNewswire-FirstCall/ -- Abbott and other leading scientists will present new...

New data demonstrate that risperidone long-acting injection extends time to relapse in patients with schizophrenia compared to those treated with oral quetiapine

Wed, 07 May 2008 19:05:18 GMT

HIGH WYCOMBE, England, 6 May 2008 - A new study, presented for the first time today at an international psychiatric meeting, examined the time to relapse in patients with schizophrenia treated with risperidone long-acting injection (RLAI) or...

Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Society's Annual Meeting

Wed, 07 May 2008 15:45:33 GMT

NEW BRUNSWICK, N.J., May 07, 2008 /PRNewswire-FirstCall/ -- Johnson & Johnson will provide a pre-recorded webcast for financial analysts on Friday, May 9 at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's (APS) annual...

XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week

Wed, 07 May 2008 15:15:48 GMT

Webcast to Review CUSTOM III Six-Month Data to be held Tuesday, May 13th MENLO PARK, Calif., May 07, 2008 /PRNewswire-FirstCall/ -- XTENT, Inc. today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR,...

Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting

Wed, 07 May 2008 15:15:17 GMT

TAMPA, Fla., May 07, 2008 /PRNewswire-USNewswire/ -- Acute pain is a significant medical issue in the United States. More than 25 million Americans are said to experience acute pain each year as a result of injuries or surgeries, and a recent study...

Steroids Provide No Survival Benefit for Children With Bacterial Meningitis

Wed, 07 May 2008 15:01:00 GMT

-Large Study Shows Benefits Differ from those in Adults- PHILADELPHIA, May 6 /PRNewswire-USNewswire/ -- Corticosteroids given to children who are hospitalized for bacterial meningitis do not provide a benefit in survival or in reduced hospital...

The Nation's Leading Plastic Surgeons Learn about ArteFill's Five Year Safety and Long-Term Efficacy Data

Wed, 07 May 2008 14:40:29 GMT

SAN DIEGO--(BUSINESS WIRE)--May 6, 2008 - Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company whose product ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of "smile line" wrinkles,...

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting

Wed, 07 May 2008 14:30:38 GMT

SAN CARLOS, Calif., May 07, 2008 /PRNewswire-FirstCall/ -- New Phase 1 clinical trial results for NKTR-118 (oral PEG-naloxol) were presented by Nektar Therapeutics this week at the Annual Meeting of the American Pain Society (APS) in Tampa, Florida....

ACE-011 Preclinical Data Published in the Proceedings of the National Academy of Sciences

Wed, 07 May 2008 14:00:28 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2008 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the publication of key preclinical data...

Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer

Wed, 07 May 2008 13:40:19 GMT

- Preliminary Phase 1 and 2 Data Expected at ASCO in June - SOUTH SAN FRANCISCO, Calif., May 06, 2008 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it has completed...

LifeCycle Pharma Announces Positive Data from LCP-AtorFen Phase II Clinical Program

Wed, 07 May 2008 13:35:11 GMT

H0RSHOLM, Denmark--(BUSINESS WIRE)--May 7, 2008 - Summary: LifeCycle Pharma successfully completes Phase II LCP-AtorFen clinical program and expects to initiate Phase III clinical program in 2H 2008 while simultaneously seeking a partner for...

Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources

Wed, 07 May 2008 13:25:44 GMT

Separate Analysis Suggests Paliperidone ER May Impact Employment Status WASHINGTON, May 07, 2008 /PRNewswire-FirstCall/ -- Patients receiving paliperidone extended-release tablets (paliperidone ER) spent significantly fewer days in the hospital, had...

Clinical Data, Inc. Presents Vilazodone Data at 2008 Annual Meeting of the APA

Tue, 06 May 2008 20:40:26 GMT

NEWTON, Mass.--(BUSINESS WIRE)--May 6, 2008 - PGxHealth, a division of Clinical Data, Inc. (NASDAQ:CLDA) and a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers,...

Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events

Tue, 06 May 2008 20:25:42 GMT

Pharmacogenetic Findings May Lead to Individualized Treatment for Schizophrenia WASHINGTON, May 06, 2008 /PRNewswire-FirstCall/ -- Data presented today on Vanda Pharmaceuticals Inc.'s investigational drug candidate, iloperidone, included its 4-week,...

Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study

Tue, 06 May 2008 19:30:20 GMT

Separate Study Showed Significantly Improved Functioning Within Three Months WASHINGTON, May 06, 2008 /PRNewswire-FirstCall/ -- Nearly half of patients with schizophrenia fail to remain on their medication treatment, which can result in a relapse of...